Autologous haematopoietic stem cell transplantation for neurological diseases

Joachim Burman, Andreas Tolf, Hans Hägglund, Håkan Askmark

ABSTRACT

Neuroinflammatory diseases such as multiple sclerosis, neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy and myasthenia gravis are leading causes of physical disability in people of working age. In the last decades significant therapeutic advances have been made that can ameliorate the disease course. Nevertheless, many affected will continue to deteriorate despite treatment, and the costs associated with disease-modifying drugs constitute a significant fiscal burden on healthcare in developed countries.

Autologous haematopoietic stem cell transplantation is a treatment approach that aims to ameliorate and to terminate disease activity. The erroneous immune system is eradicated using cytotoxic drugs, and with the aid of haematopoietic stem cells a new immune system is rebuilt. As of today, more than 1000 patients with multiple sclerosis have been treated with this procedure. Available data suggest that autologous haematopoietic stem cell transplantation is superior to conventional treatment in terms of efficacy with an acceptable safety profile. A smaller number of patients with other neuroinflammatory conditions have been treated with promising results. Herein, current data on clinical effect and safety of autologous haematopoietic stem cell transplantation for neurological disease are reviewed.

INTRODUCTION

Haematopoietic stem cell transplantation (HSCT) has been in use for treatment of malignancies since the 1950s. In the last two decades it has been used for treatment of autoimmune diseases of the nervous system such as multiple sclerosis (MS), neuromyelitis optica (NMO), chronic idiopathic demyelinating polyneuropathy (CIDP) and myasthenia gravis (MG). Treatment with HSCT operates on the basic assumption that the origin of neuroinflammatory disease lies with the immune system and is dependent on immunological memory. In difference to currently available therapies, treatment with HSCT aims to erase the erroneous immune system and enable the formation of a new and self-tolerant immune system. As a consequence, most patients will not require additional therapy after the procedure.

Basic concepts

HSCT can be performed with stem cells collected from another individual (allogeneic transplantation) or from the same patient who will receive them (autologous transplantation). Autologous HSCT is preferred for treatment of autoimmune disease, since allogeneic HSCT is associated with high treatment-related mortality (TRM), mainly due to graft versus host reactions. The procedure can be divided into four parts: the mobilisation, when drugs such as granulocyte colony-stimulating factor are administrated to mobilise haematopoietic stem cells (HSCs) from the bone marrow; the harvest, when stem cells are acquired through leukapheresis; the conditioning, when drugs, biologics and/or radiation are given to "ablate" the pathological immune system; and finally the reinfusion of autologous HSCs. To ensure that surviving lymphocytes present in the graft are eliminated, ex vivo or in vivo lymphocytic purging with antithymocyte globulin (ATG) is performed. Today, radiation and ex vivo purging are rarely used.

One common misconception is that the HSCs are the therapeutic product. HSCs do not differentiate into neurons or oligodendrocytes, and there is no evidence that they can repair damaged central nervous system (CNS) tissue. In vivo, HSCs differentiate in a haematopoietic lineage-restricted manner to erythrocytes, thrombocytes and lymphocytes, and shorten the interval of conditioning regimen-induced cytopaenias. The term ‘autologous hematopoietic stem cell transplantation’ is somewhat misleading in this regard, since the autologous stem cells are a supportive blood product that speeds recovery, rather than the focus of this therapy, and instead many favour the somewhat cumbersome terminology ‘high-dose immunosuppressive therapy with hematopoietic stem cell support’.

Another important distinction is that HSCT should be viewed as a treatment principle rather than a single treatment. Various conditioning regimens have been used to reach the goal of immunosuppression, which must be kept in mind when studies are compared. One commonly used classification of conditioning regimens is a subdivision into high-intensity regimens, including busulfan or total body irradiation (TBI); low-intensity regimens containing cyclophosphamide and ATG; and intermediate regimens such as BEAM, which is the combination of carmustine (BCNU), etoposide, cytarabine (Ara-C) and melphalan.

The adverse events of the procedure can be divided into acute toxicity and long-term side effects. Acute toxicity gives rise to the well-known and expected side effects of alopecia, anaemia, thrombocytopenia and leucopenia. Many patients also experience fever with or without bacteraemia. Such adverse events are effectively managed with supportive blood products and antibiotics. Acute
toxicity is directly related to the intensity of the conditioning regimen, with significantly more toxicity and TRM in high-intensity conditioning regimens. Long-term side effects have been less studied, and this is a serious gap in the knowledge base of this treatment. The main concerns are viral reactivations, development of secondary autoimmunity, malignancies and impaired fertility.

**A HISTORICAL PERSPECTIVE**

For a long time it was believed that the underlying defect of autoimmune diseases resided in the HSC. Early on, it was noted that haematopoietic radiation chimaeras between rodent strains that were susceptible or resistant to autoimmune disease sometimes developed disease and sometimes not, and that this propensity was generally dictated by the genotype of the bone marrow. Thus it made little sense to use autologous HSCT in the treatment of such diseases. This notion was challenged in the early 1990s, when it was demonstrated that rats with adjuvant arthritis responded just as well to autologous or syngeneic bone marrow transplantation as to grafting with allogeneic bone marrow. Soon thereafter, several groups reported on the effects of autologous or syngeneic HSCT for experimental autoimmune encephalomyelitis (EAE). These studies showed that immunosuppression by TBI or high-dose cyclophosphamide followed by HSCT could prevent the development of paralysis in SJL mice or Lewis rats. Post-transplant animals were resistant to reinduction of disease, and histological evidence of inflammation within the CNS was absent.

These early animal studies unmasked limitations of autologous HSCT because the results of autologous HSCT in SJL mice are dependent on disease stage. Animals treated early after disease induction had enduring improvement in disability, while there was no neurological improvement in animals treated in the chronic phase of EAE. EAE is an autoimmune demyelinating disease induced by vaccination with myelin epitopes, but if demyelination is due to a persistent CNS viral infection as is the case in Theiler’s murine encephalomyelitis virus-induced demyelinating disease (TMEV), HSCT results in further neurological deterioration from viral hyperinfection of the CNS. In clinical practice, neuroinflammatory disease responds to HSCT similar to the autoimmune EAE model and not the virally induced TMEV model.

Based on experiences from such animal studies, Burt et al suggested that autologous HSCT should be tried for aggressive inflammatory MS. However, when Fassas et al performed the first autologous HSCT for MS in April 1995, it was limited to secondary progressive MS for safety reasons. Their experiences with 15 patients were summarised in a seminal paper published in 1997, which set the stage for the coming years. The treatment could ‘be used with relative safety’, and some evidence was found that ‘this kind of therapy can suppress disease progression and reduce disability’. In the following years many groups reported outcome from treatment of mainly secondary progressive MS (SPMS) or primary progressive MS (PPMS) patients in small case series. With increasing experience from more centres, the results were disappointing and many patients continued to deteriorate, especially with longer follow-up.

This was forthrightly summarised by Burt et al, who reported that HSCT in secondary progressive MS with high expanded disability status scores (EDSS >6.0) was a failure and ineffective in preventing disease progression. At this point very few patients with RRMS were treated, but it was noted that patients with RRMS improved in the EDSS score and that the effect on the development of new MRI lesions was profound. In one study, the number of gadolinium-enhancing lesions was decreased from 656 in 18 patients pretherapy, to 7 post-HSCT. The turning point came in 2009, when two independent groups reported that HSCT could completely abrogate disease activity in a majority of RRMS patients. These and similar reports led to the 2012 consensus recommendations that HSCT should be considered as a therapeutic option at second line or beyond for patients with RRMS who deteriorate despite standard therapy. As a first, HSCT was approved for treatment of RRMS on the national level by the Swedish Board of Health and Welfare in 2016.

A large majority of published reports on HSCT for neurological conditions have been made on MS, reflecting the higher prevalence. Prompted by the good treatment responses in MS, HSCT was eventually tried for other neuroinflammatory diseases as well. In CIDP and MG, some case reports of successful outcome were published about 10 years ago; the first report of HSCT for CIDP appeared in 2002 and for MG in 2005. Recently a register-based study from the European Society for Blood and Marrow Transplantation (EBMT) was published, reporting outcome of patients with NMO treated with HSCT.

**MULTIPLE SCLEROSIS**

Several reports with data from the EBMT registry have been published on HSCT for MS, which highlight some of the difficulties encountered in registry-based studies. Validity of data can be put into question since registry data are not vetted by site visits for accuracy of disease stage, experience and certification of physician doing disease scoring. In addition, this group of patients is heterogeneous and has been treated with different regimens and different standard of care guidelines. Finally, the registry includes patients from centres with variable experience with the procedure, where some centres have performed only a handful of transplants, which has been identified as a risk factor for TRM. Such elements will confound data interpretation significantly.

In addition to the reports of registry data, a large number of uncontrolled studies have been published over the years. In the initial studies, clarifying outcome and toxicity between trials is complicated due to heterogeneity in disease stage (RRMS, SPMS, PPMS), entry criteria (whether by disease progression or number of relapses), conditioning regimens and treatment guidelines. A summary of these trials was recently tabulated. By now, it is established that HSCT has a profound effect on inflammation in MS and that it prevents relapses, new MRI lesions and disability in RRMS to a high degree. Whether HSCT also has a beneficial effect in SPMS or PPMS is at present unknown, and as a consequence we will summarise only the trials concerning chiefly RRMS.

We identified four studies containing at least 10 RRMS patients describing the outcome of a total of 188 RRMS patients (table 1). Further, we will discuss the recently published The Autologous Haematopoietic Stem Cell Transplantation trial in MS (ASTIMS) study, which at present is the only reported randomised controlled trial.

**Efficacy**

Only one randomised controlled trial of HSCT for MS has been reported in the literature: the ASTIMS trial, which was prematurely terminated due to slow accrual of patients. It was initially designed as a phase III trial with confirmed EDSS progression as the primary endpoint, which after an interim analysis was changed to a phase II trial with cumulative number...
of new T2 MRI lesions as the primary endpoint. Patients were eligible for the study if they had clinically definite MS (RRMS or SPMS), an EDSS score between 3.5 and 6.5, a documented worsening in the previous year, and presence of one or more gadolinium-enhancing lesions on MRI despite conventional therapy. Only 21 patients were included, of whom only 7 were RRMS patients. Nevertheless, the investigators could report a significant reduction in the formation of new T2 lesions by 79% and a reduction in annualised relapse rate by 64% versus the active comparator, which was mitoxantrone. Mitoxantrone is a well-known drug with potent and well-described effects on clinical as well as MRI outcome measures. The ASTIMS trial provides evidence for superior effect to an established drug that historically has been seen as the best option for treatment of aggressive MS.

Most of the clinical data on the effect on RRMS come from reports of uncontrolled single centres studies containing in total 247 patients with MS, of whom 188 were RRMS patients. The inclusion criteria were slightly different between studies (see online supplementary appendix), but as a rule patients had failed one or more conventional therapies with EDSS progression and/or severe relapses. Only one study contained only RRMS patients, and in some instances results from RRMS patients and patients with PPMS or SPMS were reported together. In addition, different conditioning regimens were used and patient selection varied. Nevertheless, clinical and radiological outcomes are fairly consistent between these case series.

Progression of disability
All studies reported on progression-free survival, defined as deterioration in EDSS by 0.5–1 point from baseline. Progression-free survival was 87% at 4 years and 70%–91% at 5 years, with the lowest numbers seen in cohorts containing a higher proportion of patients with SPMS. EDSS improved with 0.5–1.5 from baseline, with the greatest improvement seen in the first year after HSCT, some additional improvement in the second year, and thereafter essentially stable levels of neurological function.

Imaging
MRI provides important information about inflammation and to some extent neurodegeneration in MS. MRI event-free survival, defined as no appearance of new T2 lesions or gadolinium-enhancing lesions on T1 sequences, was 85%–86% at 5 years in two studies. Of note, MRI event-free survival was 100% in patients treated with a high-intensity conditioning regimen, with follow-up time of more than 10 years in some patients. One study reported that the mean volume of T2 lesions decreased from a pretransplant value of 15.69 cm³ to 10.92 cm³. The rate of neurodegeneration is usually estimated by measurement of brain atrophy. Brain atrophy is more pronounced in patients with MS than in age-matched controls and may be further accelerated by HSCT. It has been associated with the use of busulfan-containing high-intensity conditioning regimens, which may be neurotoxic. Other possible explanations for this phenomenon include the resolution of disease-induced oedema (pseudatrophy) and continuous neurodegeneration of structures already damaged before HSCT. Accelerated atrophy appears early after HSCT, subsides with time and eventually the brain atrophy rate reaches the levels of normal ageing, which is reassuring.

Table 1 Summary of reports of HSCT for MS

| Study          | n   | Age (years) | Disease duration (years) | Follow-up time (months) | Conditioning | Disease-free survival (%) | Timepoint | Prognostic factors |
|----------------|-----|-------------|--------------------------|-------------------------|--------------|--------------------------|-----------|--------------------|
| Burman et al   | 37  | 48          | 31†                      | 24                      | 5.54         | 61                       | 24        | RRMS vs SPMS       |
| Nash et al     | 40  | 38‡         | 24                       | 4.9‡                    | 4.5‡         | 24                       | 24        | Fever in the peritransplant period |
| Burt et al     | 38  | 151         | 37‡                      | 118                     | 61           | 24                       | 24        | Disease duration <10 years |
| Atkins et al   | 39  | 34‡         | 12                       | 12                      | 5.8‡         | 51                       | 51        | MRI-proven disability at onset of HSCT, hemanopoietic stem cell transplantation, MS multi-drug regimen, EDSS, no evidence of disease activity, T1 signal-enhancing lesions, MRI, prednisone, cyclophosphamide, melphalan, and HLA-DR mismatch |

| Burman et al   | 37  | 48          | 31†                      | 24                      | 5.54         | 61                       | 24        | RRMS vs SPMS       |
| Nash et al     | 40  | 38‡         | 24                       | 4.9‡                    | 4.5‡         | 24                       | 24        | Fever in the peritransplant period |
| Burt et al     | 38  | 151         | 37‡                      | 118                     | 61           | 24                       | 24        | Disease duration <10 years |
| Atkins et al   | 39  | 34‡         | 12                       | 12                      | 5.8‡         | 51                       | 51        | MRI-proven disability at onset of HSCT, hemanopoietic stem cell transplantation, MS multi-drug regimen, EDSS, no evidence of disease activity, T1 signal-enhancing lesions, MRI, prednisone, cyclophosphamide, melphalan, and HLA-DR mismatch |

*Only evaluated for safety.†Mean.‡Median.
No evidence of disease activity

Disease-free status, or no evidence of disease activity (NEDA), is an outcome measure that recently has gained considerable interest and has become a treatment goal in clinical practice. NEDA is usually defined as the absence of new or enlarging T2 lesions or T1 gadolinium-enhancing lesions on MRI with no sustained EDSS score progression or clinical relapse. Importantly, NEDA assessed early on predicts disability at long-term follow-up. In an unselected group of patients, such as the Comprehensive Longitudinal Investigation of Multiple Sclerosis at Brigham and Women’s Hospital cohort, NEDA was 7.9% at 7 years, even though a majority of patients were treated with standard disease-modifying therapy. Even with advanced immunotherapy, such as natalizumab or alemtuzumab, only 32%–39% maintained NEDA at 2 years in phase III clinical trials. In contrast, 68%–70% of patients treated with HSCT maintained NEDA at 4–5 years after transplant.

Quality of life

Patient-perceived health status and health-related quality of life (HRQoL) are measures of patients’ condition and treatment outcome that have been increasingly recognised. In particular, MS is associated with a poor HRQoL, which deteriorates with disease progression, affecting family life, social functioning and employment status. HRQoL assessment may be especially important in the evaluation of treatment with HSCT. Serious adverse events and impaired fertility may significantly reduce HRQoL. On the other hand, HSCT is a one-time procedure that potentially can reverse disability, which could improve HRQoL.

Two studies evaluated HRQoL before and after HSCT. One study used the 36-Item Short Form Survey (SF-36) instrument, where a change in five points or more is accepted as a clinically meaningful improvement. After a median follow-up time of 2 years, the SF-36 scores improved significantly by 19 points for total health (15 points for physical health and 20 for mental health). In contrast, natalizumab and dimethyl fumarate failed to show clinically meaningful improvement in HRQoL on the SF-36 in the phase III trials. In the second study HRQoL was evaluated with the Multiple Sclerosis Impact Scale (MSIS-29), where a change in eight points or more is considered clinically meaningful. After 3 years, the investigators found that the median MSIS-29 score had improved by 15 points. The MSIS-29 has seen less use than SF-36, but was employed to evaluate HRQoL in a postmarketing investigation of natalizumab in Sweden, but again the investigators failed to show a clinically meaningful difference.

Safety and adverse effects

Safety of the procedure has been a major concern, and historically HSCT has been viewed as a high-risk procedure. In a 2006 report from the EBMT register, a TRM of 5.3% in 183 examined patients was reported. A high-intensity conditioning was associated with increased mortality and prolonged hospitalisation. In a later follow-up of EBMT data from 345 patients with MS, TRM had decreased to 3.8%. In a pooled analysis of patients with different autoimmune diseases, age <35 years and centre’s experience were associated with lower risk of death (HR 1.7 for age and HR 2.5 for centre experience).

With experience, better patient selection and refinement of the procedure, these numbers have improved significantly. In a recent meta-analysis TRM was 0.3% in procedures performed after 2005 and nil in patients treated with a low-intensity conditioning regimen. To put these numbers in perspective, TRM in phase II and III studies for alemtuzumab was 0.3% and the risk of contracting progressive multifocal leucoencephalitis in JC virus-positive patients treated with natalizumab is about 1% per year.

Long-term side effects have been less studied. A common side effect is herpes zoster reactivation, which has been reported in 2.6%–26% of patients, mainly dependent on the length of viral prophylaxis and the intensity of the conditioning regimen. This usually manifests as shingles, which is manageable with oral acyclovir. One concern is the development of secondary autoimmunity, such as thyroid disease, which occurs in 4.0%–17% of patients with MS after HSCT. Idiopathic thrombocytopenic purpura (ITP) after HSCT has also been reported in a few cases, and therefore physicians should be on alert for these potentially serious adverse effects. The risk of development of malignancies and ovarian failure is unknown, but is likely related to the intensity of the conditioning regimen.

Summary

Although head-to-head comparisons with other disease modifying drug (DMDs) are essentially lacking, available data suggest that HSCT for MS is superior to currently approved DMDs. The safety profile of the procedure has been improved in later years, and TRM is now on par with generally accepted procedures such as arthroplasty. Other serious adverse events include secondary thyroid disease and ITP, occurring to a lesser degree than with comparable advanced forms of immunotherapy, such as alemtuzumab. In light of the above, the procedure could be recommended for RRMS patients with an unfavourable prognosis despite treatment with alternate approved therapy, who seek treatment at experienced centres. Current data suggest that the effect of HSCT in SPMS and PPMS is moderate at best, and further use should be limited to clinical trials.

Neuromyelitis optica

NMO and NMO spectrum disorders (NMOSD) are autoimmune diseases of the CNS primarily affecting the optical nerves and spinal cord. The presence of IgG autoantibodies to water channel aquaporin-4 (AQP4-IgG) is highly specific for these conditions and potentially pathogenic. The prognosis is poor due to respiratory failure and severe visual loss due to optic neuritis. Treatment includes immunosuppressive and immunomodulatory drugs such as azathioprine and rituximab, but randomised controlled studies are lacking.

The use of autologous HSCT for treating NMO was first described in a 2010 case report. The patient was a 23-year-old woman with a severe and rapidly disabling disease course: vision loss, paraparesis, dysaesthesia and radical pain. Two years after disease onset, she was treated with HSCT using a BEAM conditioning regimen. At follow-up 12 months after the procedure, the patient was stable with no further relapses and normalised motor and sensory functions. Visual acuity had improved only slightly, but optic nerve atrophy was present before treatment.

In 2014 data from a retrospective multicentre study based on data from the European Group for Blood and Marrow Transplantation Autoimmune Diseases Working Party were presented. Sixteen patients (13 women, 3 men) with NMO or NMOSD, refractory to other treatment, underwent autologous HSCT between 2001 and 2011. The median age at NMO diagnosis was 29 (range 10–56) and the median time from diagnosis to transplant was 2 years (range <1–17). The median EDSS at baseline was 6.5 (range 2.8) and 10/16 patients had AQP4-IgG at diagnosis. Nine patients were treated with an intermediate...
BEAM-based conditioning regimen; the remaining seven patients had a lower intensity regimen based on Cy plus ATG or thiotepa-Cy alone. The median follow-up was 47 months (range 20–128). Thirteen patients (81%) had a relapse after a median of 7 months (range <1–57) and nine patients (56%) experienced progression of disability. The estimated relapse-free survival after 3 years was 31% (±12%) and after 5 years 10% (±9%); progression-free survival was 48% (±13%) after both 3 and 5 years. In total, three patients were stable and required no other treatment; the other 13 patients required further treatments after HSCT. One patient died from disease progression 14 months after HSCT. The serostatus of AQP4-IgG was unchanged in the eight AQP4-IgG seropositive patients, who were retested after HSCT.

Three of the patients who relapsed after autologous HSCT in the above-mentioned study were further treated with allogeneic HSCT, and the outcome of two of those patients (one man, one woman) was described by Greco et al in 2014.46 Both patients reached clinical remission and improved in disability; EDSS had decreased from 6 to 3.5 and from 8.5 to 7.5 at follow-up after 4 and 3 years, respectively. No new relapses were observed, and in both patients AQP4-IgG went from positive to negative after treatment.

Aouad et al47 reported a single case of a 47-year-old woman with NMO and high titres of AQP4 antibodies who underwent autologous HSCT with a disease duration of 11 years. The patient was given two doses of rituximab, as a part of the conditioning regimen (Cy plus ATG). At follow-up 6, 9 and 12 months after treatment, AQP4-IgG could not be detected; she had no relapse, no clinical progression and no new lesions on MRI.

Currently available data suggest that autologous HSCT can reduce inflammatory activity in NMO in the short term, but a vast majority of patients will relapse within 5 years. Conditioning regimens containing rituximab and allogeneic HSCT may improve prognosis, although the few cases described prohibit any firm conclusions.

STIFF PERSON SYNDROME
Stiff person syndrome (SPS) is a rare autoimmune central nervous system disorder characterised by muscle stiffness and superimposed painful muscle spasms and frequently by the presence of antibodies against glutamic acid decarboxylase (GAD). Many patients respond to immune modulating therapy, but symptomatic treatment with GABAergic drugs such as benzodiazepines and baclofen may also be helpful. Sanders et al48 reported two cases with severe anti-GAD positive SPS, who underwent HSCT with a high intensity conditioning protocol49. The follow-up time was 56 and 32 months respectively. Both patients achieved clinical remission with a return to premorbid function and neither experienced any unexpected serious adverse events. In one of the patients anti-GAD antibodies decreased from 127 U/mL before HSCT to 87 U/mL two months after the procedure.

Available data provide preliminary evidence that HSCT may be an effective therapeutic option in carefully selected cases of severe, treatment refractory SPS.

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
CIDP is a disease targeting myelin in the peripheral nervous system. Approximately 80% of patients will respond adequately to first-line treatment,71 but of those 12%–29% eventually become treatment-refractory.72 73 If not treated efficiently secondary axonal loss will accumulate over time, increasing the level of morbidity and risk of mortality.74 Severe disability despite treatment is seen in 13% of patients and mortality rates vary between 4% and 17%, mainly due to respiratory failure or pulmonary embolism.72 75 Treatment-refractory patients with CIDP are usually treated with second-line immunomodulatory drugs such as cyclophosphamide, ciclosporin, rituximab, azathioprine and methotrexate, although evidence for the efficacy of these treatments is lacking.76 77

The use of autologous HSCT in treatment-refractory CIDP was first reported in 2002 by Vermuelen and Van Oers31, who used a BEAM conditioning protocol. The response was maintained until 5 years post-transplant when symptoms recurred.78 79 This initial report has been followed by mainly case reports of up to three patients,79–82 with one notable exception. In the as of yet largest documented series of patients with CIDP receiving HSCT, Press et al83 described 11 patients refractory to first-line treatment, and in 10 of them also to one or more second-line treatments. They received HSCT at four different university hospitals in Sweden between 2002 and 2012. The total Inflammatory Neuropathy Cause and Treatment (INCAT) scale and Rankin scores improved significantly within 2–6 months after HSCT and continued to do so at last follow-up. The motor action potential amplitudes improved rapidly within 4 months after the procedure. Eight of the 11 patients maintained drug-free remission at last follow-up after HSCT, and only three patients experienced a relapse. The procedure was generally speaking safe with no TRM, but adverse events included asymptomatic and symptomatic cytomegalovirus and Epstein-Barr virus reactivation, haemorrhagic cystitis and pancreatitis. Of note, one of these patients received HSCT twice due to a post-HSCT relapse. After the second HSCT the patient had a 3-month episode of fever, bronchitis and elevated liver enzymes probably related to Epstein-Barr and cytomegalovirus reactivation.84

Bregante et al85 described a patient with Sjögren’s syndrome-associated CIDP, who first responded to HSCT, but got a relapse after 6 months, which was treated successfully with allogeneic HSCT. The patient also developed aplastic anaemia at the time of the neurological relapse.

We could identify reports containing in total 20 patients with treatment-refractory CIDP receiving HSCT at 10 different centres (table 2). Four were treated with the intermediate-intensity BEAM conditioning regimen, and the remainder with low-intensity cyclophosphamide-based protocols. Ninety per cent of the patients improved after the procedure, and 35% experienced a relapse. The most common adverse events (apart from the expected adverse events related to acute toxicity) were asymptomatic and symptomatic cytomegalovirus and Epstein-Barr virus reactivation.

These published cases, which include our own experiences, suggest that HSCT may be a treatment that may induce long-term remission even in severe treatment-refractory cases of CIDP with an overall acceptable risk profile. To improve outcome, treatment should preferably be initiated before irreversible axonal damage has occurred. A more precise estimation of the clinical efficacy of HSCT for CIDP will require a randomised controlled trial.

OTHER PERIPHERAL NEUROPATHIES
Antimyelin-associated glycoprotein (MAG) neuropathy is an antibody-mediated demyelinating neuropathy clinically characterised by distal, symmetric, predominantly sensory symptoms. Immunomodulating therapies are often tried, but there is insufficient evidence for their effect.86 In the report by Mahdi-Rogers...
et al mentioned above,,89 the authors also described a patient with demyelinating polyneuropathy with IgM paraproteinaemia and MAG antibodies who first improved after HSCT, but relapsed after 30 months.

Multifocal motor neuropathy (MMN) is an uncommon immune-mediated, slowly progressive, purely motor neuropathy that is characterised by the presence of multifocal conduction blocks in motor nerves and frequently serum anti-GM1 antibodies. IVIg is to date the only therapy with proven efficacy providing transient improvement in muscle strength. A single report describes a patient with MMN who responded to IVIg providing transient improvement in muscle strength. A single report of one patient with intractable MG undergoing allogeneic HSCT describes a treatment-free remission with minor adverse events after 2 years. However, there were no HSCT-related adverse events during the 6-month follow-up.

Bryant et al94 reported seven cases of severe MG treated with HSCT. Six patients underwent HSCT for MG and one for follicular lymphoma with coincident active MG. Mean ages at MG diagnosis and at HSCT were 37 (±11) and 44 (±10) years, respectively. Five patients had acetylcholine receptor antibodies and two were seronegative. MG severity was graded as moderate (grade III) to life-threatening (grade V) by the Myasthenia Gravis Foundation of America (MGFA) clinical classification, and patients were refractory to treatments including pyridostigmine, corticosteroids, additional immunomodulators and plasma exchange or IVIg. Four patients had previously undergone thymectomy; none had thymoma. All patients received high-intensity conditioning regimens containing TBI or busulfan, leading to durable remission with no residual MG symptoms and freedom from ongoing MG therapy in all patients. The median follow-up was 40 months (range 9–149 months). Acetylcholine receptor antibodies were not analysed after HSCT. Three patients experienced transient viral reactivations and one developed a secondary autoimmune disease after HSCT, all of which resolved or stabilised with treatment.

Håkansson et al95 described a patient with severe MG, diagnosed at the age of 26, refractory to corticosteroids, four oral immunosuppressants, cyclophosphamide, rituximab and bortezomib. At the age of 63, she was treated with HSCT with the intermediate BEAM conditioning regimen. At follow-up 2 years after the procedure, the patient had significantly improved in objective tests (MG composite score decreasing from 64 to 6). Diplopia was her only remaining symptom and she was off all medications for MG. Interestingly, acetylcholine receptor antibodies were still detectable after HSCT. No serious adverse events were reported.

A single report of one patient with intractable MG undergoing allogeneic HSCT describes a treatment-free remission with minor adverse events after 2 years. However, there were no HSCT-related adverse events during the 6-month follow-up.

| Table 2 | Summary of reports of HSCT for CIDP |
|---------|-----------------------------------|
| **n**  | **Age at onset** | **Gender** | **Disease duration (months)** | **Conditioning** | **Clinical outcome** | **Duration of follow-up (months)** | **Relapse (months after HSCT)** |
|---------|------------------|-----------|-----------------------------|------------------|----------------------|-------------------------------|-----------------------------|
| Vermeulen et al81 | 1 | 38 | M | 120 | BEAM | Good recovery, but still on prednisone 5mg/day and relapse after 5years | >60 | 60 |
| Kamat et al82 | 2 | 42 | M | 24 | Cy+ATG | Unable to walk to ambulant | 18 | None |
| | 72 | M | 120 | Cy+ATG | Stabilised | 3 | None |
| Oyama et al83 | 1 | 32 | F | 30 | Cy+ATG | Rankin functional score from 4 to 1 | 22 | None |
| Barreira et al84 | 1 | 24 | M | 144 | Cy+ATG | Short transient response | 2 | 1 |
| Mahdi-Rogers et al85 | 3 | 29 | F | 252 | Cy+ATG | MRC sum score 39–48–29 | 26 | 18 |
| | 58 | F | 156 | Cy+ATG | MRC sum score 58–62 | 6 | None |
| | 72 | M | 72 | Cy+ATG | MRC sum score 46–34 | 19 | None |
| Axelson et al86 | 1 | 56 | M | 11 | Cy | INCAT score from 10 to 2 | 101 | 25 |
| | | 36 | Cy+ATG | INCAT score from 6 to 2 | None | |
| Press et al87 | 11 | 16–67 | 10 M, 1 F | 11–228 | CY+ATG (7) | Median INCAT score from 6 to 1 | 6–101 | 23 |
| | | | | BEAM (3) | | 23 | None |
| | | | | Melphalan (1) | | 14 | None |
| Bregante et al88 | 1 | 24 | M | 7 | Thiopeta+Cy+G-CSF | Wheelchair users to ambulant for 6 months | 60 | 6 |
| | | | | Fludarabin+Cy+TBI* | Unable to walk to ambulant | None | |

*All HSCT. ATG, antithymocyte globulin; CIDP, chronic idiopathic demyelinating polyneuropathy; HSCT, haematopoietic stem cell transplantation; TBI, total body irradiation; BEAM, the combination of carmustine (BCNU), etoposide, cytarabine (Ara-c), and melphalan; Cy, cyclophosphamide; G-CSF, granulocyte colony stimulating factor; MRC, Medical Research Council Scale for Muscle Strength; INCAT, Inflammatory Neuropathy Cause and Treatment Scale.

MYASTHENIA GRAVIS

MG is neurological disease with immune reactivity against the postsynaptic endplate of the neuromuscular junction.91 Apart from symptomatic treatment with cholinesterase inhibitors, many patients also require immunomodulatory treatment. The prevalence of treatment-refractory MG has been estimated to be 10% of patients with generalised disease.92 93

The use of autologous HSCT in MG was first reported in 2004 by Burt et al.32 who employed a low-intensity conditioning regimen. The patient, a 30-year-old woman with severe therapy-resistant anti-muscle specific kinase (MUSK) positive MG (Osserman grade IIB/III), was free from symptoms (Osserman grade 0) 2 months after HSCT, and prednisolone could be tapered after 4 months. There were no HSCT-related adverse events during the 6-month follow-up.

Bryant et al94 reported seven cases of severe MG treated with HSCT. Six patients underwent HSCT for MG and one for follicular lymphoma with coincident active MG. Mean ages at MG diagnosis and at HSCT were 37 (±11) and 44 (±10) years, respectively. Five patients had acetylcholine receptor antibodies and two were seronegative. MG severity was graded as moderate (grade III) to life-threatening (grade V) by the Myasthenia Gravis Foundation of America (MGFA) clinical classification, and patients were refractory to treatments including pyridostigmine, corticosteroids, additional immunomodulators and plasma exchange or IVIg. Four patients had previously undergone thymectomy; none had thymoma. All patients received high-intensity conditioning regimens containing TBI or busulfan, leading to durable remission with no residual MG symptoms and freedom from ongoing MG therapy in all patients. The median follow-up was 40 months (range 9–149 months). Acetylcholine receptor antibodies were not analysed after HSCT. Three patients experienced transient viral reactivations and one developed a secondary autoimmune disease after HSCT, all of which resolved or stabilised with treatment.

Håkansson et al95 described a patient with severe MG, diagnosed at the age of 26, refractory to corticosteroids, four oral immunosuppressants, cyclophosphamide, rituximab and bortezomib. At the age of 63, she was treated with HSCT with the intermediate BEAM conditioning regimen. At follow-up 2 years after the procedure, the patient had significantly improved in objective tests (MG composite score decreasing from 64 to 6). Diplopia was her only remaining symptom and she was off all medications for MG. Interestingly, acetylcholine receptor antibodies were still detectable after HSCT. No serious adverse events were reported.

A single report of one patient with intractable MG undergoing allogeneic HSCT describes a treatment-free remission with minor adverse events after 2 years. However, there were no HSCT-related adverse events during the 6-month follow-up.
residual symptoms at 40 months after transplantation. The role of autologous HSCT in a disease as MS should be limited due to its high risk of mortality and the possible occurrence of secondary MG as a manifestation of graft versus host disease.

Available data provide preliminary evidence that HSCT can be an effective therapeutic option in carefully selected cases of severe, treatment-refractory MG.

CONCLUDING REMARKS

In this review, we have summarised the past 20 years of experience with autologous HSCT for neurological diseases. The vast majority have been patients with MS, and by now more than 1000 individuals have been treated with this procedure. Available data are very consistent on ‘no evidence of disease activity’, and 68%–70% of RRMS patients will remain in NEDA 5 years after HSCT regardless of conditioning regimen. Safety has been improved and the TRM has been estimated at 0.3% in the last decade. These numbers compare favourably with conventional treatment and open up for a more widespread use. Although considerably fewer patients with MG and inflammatory neuropsychopathies have been treated so far, the reported outcome looks promising and should be followed by formalised clinical trials. Meanwhile, the procedure could be considered in patients with severe treatment-resistant disease. In contrast, HSCT does not seem to be able to contain disease activity in NMO, and further use outside of clinical trials is questionable at best.

REVIEW CRITERIA

A search for original articles was performed in Medline and PubMed. The search terms ‘multiple sclerosis’, ‘neuromyelitis optica’, ‘chronic inflammatory demyelinating polyneuropathy’, ‘multifocal motor neuropathy’, ‘inflammatory neuropathy’, ‘peripheral neuropathy’, ‘myasthenia gravis’, ‘hematopoietic stem cell transplantation’, ‘relapsing-remitting’ and ‘clinical trial’ were used alone or in combination. The reference lists of identified articles were scrutinised for further relevant papers.

For efficacy in MS, we included only those reports that included at least 50% RRMS patients and reported the outcome of at least 10 patients. Four studies were found using this strategy. In addition, we included the only randomised controlled trial that was identified, although it mainly contained data on SPMS patients.

For NMO we included all relevant reports found using this strategy.

For SPS we included all relevant reports found using this strategy.

For CIDP and other inflammatory polyneuropathies we included all relevant reports found using this strategy.

For MG we included all relevant reports found using this strategy.

Contributors JB initiated and outlined this review. JB and AT wrote the sections on HSCT for diseases of the peripheral nervous system. HH reviewed the haematological aspects. All authors revised the manuscript critically for intellectual content.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Thomas ED, Lochte HL, Cannon JH, et al. Suralthelal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 1959;38:1709–16.
2. McFarland W, Granville NB, Dameshek W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood 1959;14:503–21.
3. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European group for blood and marrow transplantation working party on Autoimmune diseases. Haematologica 2010;95:284–92.
4. Ikehara S, Kawamura M, Takao F, et al. Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells. Proc Natl Acad Sci U S A 1990;87:8341–4.
5. Kraan-Shanser S, Houben P, Kinwel-Bohré EP, et al. Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation. Bone Marrow Transplant 1991;8:333–8.
6. Karussis DM, Slavin S, Lehmann D, et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol 1992;148:1693–8.
7. Karussis DM, Vourka-Karussis U, Lehmann D, et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest 1995;92:765–72.
8. van Gelder M, Kinwel-Bohré EP, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with total body irradiation and autologous BMT. Bone Marrow Transplant 1993;11:233–41.
9. Burt RK, Burns W, RuvoI P, et al. Syngeneic bone marrow transplantation eliminates V beta 8.2 T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 1995;41:526–31.
10. van Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant 1996;18:1029–34.
11. Burt RK, Padilla J, Begolka WS, et al. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 1998;91:2609–16.
12. Burt RK, Padilla J, Dal Canto MC, et al. Viral hyperinfection of the central nervous system and high mortality after hematopoietic stem cell transplantation for treatment of Thieier’s murine encephalomyelitis virus-induced demyelinating disease. Blood 1999;94:2915–22.
13. Burt RK, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplantation 1995;16:1–4.
14. Fassas A, Anastopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997;20:631–8.
15. Fassas A, Anastopoulos A, Kazis A, et al. Autologous stem cell transplantation in progressive multiple sclerosis—an interim analysis of efficacy. J Clin Immunol 2000;20:24–30.
16. Kozák T, Havrdová E, Pita L, et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000;25:525–31.
17. Openshaw H, Lund BT, Kashyap A, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000;6:563–75.
18. Burt RK, Cohen BA, Russell E, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003;102:2373–8.
19. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003;102:2364–72.
20. Saiz A, Blanco Y, Carreras E, et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology 2004;62:282–4.
21. Saccardi R, Mancardi GL, Solari A, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005;105:2601–7.
22. Samijn JP, te Boekhorst PA, Mondria I, et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006;77:746–50.
23. Xu J, Ji BX, Su L, et al. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J 2006;119:1851–5.
24. Krasulova E, Trnery M, Kozak T, et al. High-dose immunosuppression with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 2010;16:685–93.
25. Fassas A, Kimmiskis V, Sakellari I, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 2011;76:1066–70.
26. Saccardi R, Kozak T, Bocelli-Tyndall C, et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow
Transplantation autoimmune diseases working party database. *Multiple Sclerosis* 2006;12:814–23.

27 Fagius J, Lundgren J, Obeg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. *Mult Scler* 2009;15:229–37.

28 Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase III study. *Lancet Neurol* 2009;8:244–53.

29 Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant* 2012;47:770–90.

30 Vând vid multipel skleros och Parkinsons sjukdom. SBotha W, ed., 2016:26–30.

31 Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. *J Neurol Neurosurg Psychiatry* 2002;72:127–8.

32 Burt R, Statkute L, Gourineni R, et al. Treatment of refractory myasthenia gravis with high dose chemotherapy and autologous hematopoietic stem cell transplantation. *Neurology* 2004;62:A497.

33 Greco R, Bondanza A, Oliveira MC, et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT autoimmune diseases working party. *Mult Scler* 2014;20:1124–30.

34 Fassas A, Passweg JR, Anagnostopoulos A, et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. *J Neurol Neurosurg Psychiatry* 2002;74:1088–97.

35 Saccardi R, Kozak I, Boeili-Tyndall C, et al. Autologous stem cell transplantation for progressive multiple sclerosis: a case series update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. *Mult Scler* 2006;12:814–23.

36 Radaelli M, Merlini A, Greco R, et al. Autologous bone marrow transplantation for the treatment of multiple sclerosis. *Curr Neurol Neurosci Rep* 2014;14:478.

37 Burman J, Iacobaeus E, Svenningsson A, et al. Autologous haemopoietic stem cell transplantation following non-myeloablative conditioning for multiple sclerosis: the Swedish experience. *J Neurol Neurosurg Psychiatry* 2014;85:1116–21.

38 Atkins HL, Burman J. Mult Scler 1999;53:1107–14.

39 Fox RJ, Gold R, et al. Health-related quality of life in multiple sclerosis: a systematic review. *J Neurol* 2006;253:132.

40 van Doorn PA, Hughes RA. Multiple Sclerosis. *Br J Neurosurg* 2003;17:356–63.

41 Barsi R, Berti F, Mancardi GL, et al. Allogeneic hematopoietic stem cell transplantation for multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet* 2012;380:1819–28.

42 Coles AJ, Tewson T, et al. Alemtuzumab versus interferon beta-1a in early multiple sclerosis. *N Engl J Med* 2008;359:1786–801.

43 Cain JA, Kundukulam J, Ridgway J. Report of a joint registry mortality following joint arthroplasty: a systematic review. *J Rheumatol* 2011;38:1507–13.

44 Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology* 2015;85:177–89.

45 Wingerchuk DM, Hogancamp WF, O’Brien PC, et al. The clinical course of neuromyelitis optica (Devic’s syndrome). *Neurology* 1999;53:1107–11.

46 Pesci F, Qiu W, Li J, et al. A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation. *Neurologist* 2010;16:375–8.

47 Greco R, Bondanza A, Oliveira MC, et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT autoimmune diseases Working Party. *Mult Scler* 2015;21:189–97.

48 Coles RJ, Bondanza A, Varghese J, et al. Allogeneic hematopoietic stem cell transplantation in neuromyelitis optica. *Ann Neurol* 2014;75:447–53.

49 Arazur P, Li J, Arthur C, et al. Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant. *Clin Neurology* 2015;22:1215–7.

50 Sanders S, Bredeson C, Pinel CE, et al. Autologous stem cell transplantation for stiff person syndrome: two cases from the Ottawa blood and marrow transplant program. *JAMA Neurol* 2014;71:1296–9.

51 Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. *Eur J Neurol* 2010;17:289–94.

52 Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. *Neurology* 1999;52:498–503.

53 Gorson KC, van Schaijk IH, Merkies IS, et al. Chronic inflammatory demyelinating polyradiculoneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. *J Peripher Nerv Syst* 2010;15:326–33.

54 Kuwabara S, Misawa S, Mori M, et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. *J Neurol Neurosurg Psychiatry* 2006;77:66–70.

55 Lunn MP, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. *J Neurol Neurosurg Psychiatry* 1999;66:677–80.

56 Van den Bergh FJK, Hadden RDM, Bouche P, et al. European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyneuropathy. *Clin Ther* 2015;37:147–155. doi:10.1016/j.clinthera.2015.01.001

57 Costello L, O’Rourke K, Keanehy E, et al. The patient knows best: significant change in the physical component of the multiple sclerosis impact scale (MSIS-29 physical). *J Neurol Neurosurg Psychiatry* 2007;78:841–4.

58 Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALMMS): a 3-year interim report. *JAMA Neurol* 2015;72:159.

59 Sormani MP, Muraro PA, Schiavetti L, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis. *Neurology* 2017;88:2115–22.

60 Coles AJ, Compston DA, Selmaj KW, et al. Alemotuzumab versus interferon beta-1a in early multiple sclerosis. *N Engl J Med* 2008;359:1786–801.

61 Geh J, Kundukulam J, Ridgway J. Report of a joint registry mortality following joint arthroplasty: a systematic review. *J Rheumatol* 2011;38:1507–13.

62 Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology* 2015;85:177–89.
84 Axelson HW, Oberg G, Askmark H. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. J Neurol Neurosurg Psychiatry 2008;79:612–4.
85 Bregante S, Guandalini F, van Lint MT, et al. Sjögren’s syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT). Bone Marrow Transplant 2013;48:1339–40.
86 Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2016;10:CD002827.
87 Axelson HW, Oberg G, Askmark H. No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy. Acta Neurol Scand 2008;117:432–4.
88 Gronier S, Delmont E, Legros L, et al. Efficacy of autologous peripheral blood stem cell transplantation (auto-PBSC) on the neuropathic manifestations in POEMS syndrome. Rev Neurol 2014;170:37–45.
89 Arana C, Pérez de León JA, Gómez-Moreno G, et al. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) treated with autologous hematopoietic stem cell transplantation: a case report and literature review. Am J Case Rep 2015;16:124–9.
90 Nakaseko C. Autologous stem cell transplantation for POEMS syndrome. Clin Lymphoma Myeloma Leuk 2014;14:21–3.
91 Berrh-Akinin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 2014;52:90–100.
92 Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 2013;86:255–60.
93 Zebedast N, Patwa HS, Novella SP, et al. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010;41:375–8.
94 Bryant A, Atkins H, Pringle CE, et al. Myasthenia Gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol 2016;73:652–8.
95 Häkansson I, Sandstedt A, Lundin F, et al. Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis - a case report. Neuromuscul Disord 2017;27:90–3.
96 Strober J, Cowan MJ, Horn BN. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 2009;66:659–61.